Colinz Laboratories Ltd (COLINZ) is currently trading at 66.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Colinz Laboratories Limited is a pharmaceutical company established in 1986, focusing on manufacturing diverse dosage forms like tablets, capsules, and injectables. The company operates a WHO-compliant plant in Sinnar, coupled with a comprehensive quality control laboratory, supporting its emphasis on quality production. Specialized products in Gynaecology and Cardiology help Colinz establish a strong domestic brand presence, especially among gynaecologists. As an MSME, Colinz is poised for growth by expanding its marketing operations across more Indian states when economically viable. The company’s technical expertise is backed by a competent and FDA-approved staff with extensive experience across various therapeutic segments.

Over the past 52 weeks, Colinz Laboratories Ltd has traded between a low of ₹36.11 and a high of ₹87.91. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Colinz Laboratories Ltd has a market capitalization of approximately 16.75. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Colinz Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 6.03 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 16.75 Cr, Colinz Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Colinz Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Colinz Laboratories Ltd is 6.03. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The open offer is at ₹54 per share for up to 6,54,966 equity shares, representing 26% of the company’s voting share capital on a fully diluted basis.

The open offer is priced at ₹54 per share and is for up to 6,54,966 equity shares, representing 26% of the company’s voting share capital.

The company submitted newspaper clippings of its FY26 audited financial results published in Free Press Journal and Navshakti to comply with SEBI LODR Regulation 47(3).